Stock Information
symbol line chart

ICADIcade

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

N/A

Location

N/A, France

Exchange

N/A

Summary

N/A

Company Info

CEO

N/A

Location

N/A, France

Exchange

N/A

Summary

N/A

AI Insights for ICAD
5 min read

Quick Summary

iCAD, Inc. is a healthcare technology company focused on artificial intelligence solutions for cancer detection, especially breast cancer screening. The company sells software that helps radiologists and imaging centers analyze mammograms, evaluate breast density, and assess breast cancer risk. Its primary customers include hospitals, breast imaging centers, radiology groups, healthcare systems, and distribution partners that serve medical imaging providers. Recent news indicates that the company is expanding internationally through cloud-based delivery and new distribution relationships in Europe, the Middle East, Africa, and Latin America. Although the provided fundamental dataset lists the company name as Icade and a French city, the operating details, SIC code, and news flow point to iCAD, Inc. as a medical imaging AI company rather than a real estate company.

Strengths

•

iCAD’s main strength is its specialized focus on AI-powered breast imaging and cancer detection.

•

The company’s ProFound Breast Health Suite has a global footprint and is reportedly used in more than 50 countries.

•

Its technology has analyzed more than 40 million mammograms worldwide over the past five years, which supports credibility with clinicians and healthcare systems.

•

The new ProFound Cloud platform may improve scalability by reducing the need for traditional on-premises infrastructure.

•

Partnerships with distributors and healthcare technology companies can help the company expand into markets where direct sales coverage would be more difficult or expensive.

Key Risks

•

A key risk is that hospitals and imaging centers may adopt competing AI tools from larger or better-capitalized companies.

•

Regulatory delays, changing medical device requirements, or country-specific approval barriers could slow international growth.

•

Cybersecurity and data privacy risks are especially important because ProFound Cloud processes sensitive medical imaging data.

•

Financial risk is also meaningful because the company is not profitable and may need to manage cash carefully if revenue growth disappoints.

What to Watch

During the most recent reported period, iCAD highlighted momentum around ProFound Cloud, its secure SaaS platform for AI-powered breast cancer detection.
The company announced participation in the 72nd Journées Francophones de Radiologie meeting in Paris, where it planned to premiere ProFound Cloud to an international audience.
Management reported that ProFound Cloud processed nearly 100,000 cases during its first two full quarters of U.S. availability.
The company also emphasized that the platform delivers processing speeds more than 50% faster than many traditional on-premises systems.
In addition, iCAD pointed to distribution partnerships in markets such as the Dominican Republic, France, Spain, Turkey, and the United Arab Emirates, along with regulatory clearances in South Africa and the UAE.

Price Drivers

•

The stock price is likely driven by revenue growth, cash burn, profitability progress, regulatory milestones, and adoption of the company’s AI breast imaging products.

•

The provided fundamentals show negative earnings, with BasicEPS of -0.03, net income of -833,000, and operating income of -1,129,000, so investors may focus heavily on whether losses narrow over time.

•

Valuation metrics such as EVToRevenue of 4.4133 and PriceToBookValue of 3.4499 suggest the market is assigning value to future growth rather than current profitability.

•

Product adoption metrics, such as ProFound Cloud case volume, distribution partnerships, and international regulatory clearances, can meaningfully influence sentiment.

•

Broader market appetite for small-cap healthcare AI stocks, interest rates, hospital spending trends, and regulatory developments in medical AI are also important price drivers.

Recent News

•

iCAD announced that it would participate in the 72nd Journées Francophones de Radiologie meeting in Paris from October 4 to October 7.

•

At the event, the company planned to premiere ProFound Cloud, its secure SaaS platform for AI-powered breast cancer detection.

•

The company said the platform is built on Google Cloud Platform and has processed nearly 100,000 cases during its first two full quarters of U.S. availability. iCAD also highlighted recent distribution partnerships in the Dominican Republic, France, Spain, Turkey, and the United Arab Emirates, as well as relationships with companies such as Tamer, Ozel, and deepc.

•

The company also noted regulatory clearances for ProFound AI in South Africa and the UAE, which may support continued international expansion.

Market Trends

•

The medical imaging market is increasingly adopting artificial intelligence to address radiologist shortages, rising scan volumes, and the need for more consistent diagnostic support.

•

Breast cancer screening is a particularly attractive area because large screening programs generate high volumes of mammograms that can benefit from workflow automation and decision support.

•

Cloud-based healthcare software is also gaining traction because it can simplify deployment, enable continuous updates, and reduce local infrastructure burdens.

•

At the same time, medical AI buyers are demanding stronger clinical evidence, regulatory compliance, cybersecurity protections, and clear return on investment.

•

These trends create growth potential for iCAD, but they also attract intense competition from major imaging companies and specialized AI startups.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on ICAD

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show